Furosemide vs Torsemide: Similar Outcomes Observed in Heart Failure Study
The phase 3 TRANSFORM-HF trial enrolled nearly 3000 hospitalized patients with heart failure.
CHF and Arrhythmias
October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
FDA to Review Expanded Use for Mavacamten to Reduce Need for SRT
Mavacamten is an oral, selective allosteric inhibitor of cardiac myosin.
Etripamil Nasal Spray Looks Promising for Self-Administered PSVT Treatment
Etripamil is a self-administered nasal spray designed to be a rapid-response therapy for episodic cardiovascular conditions.
MPR Weekly Dose Podcast #134
Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.
FDA Approves Wearable Furosemide Delivery System Furoscix for Outpatient Use
Furoscix is a pH-neutral formulation of furosemide designed for SC administration via a wearable, single-use, pre-programmed on-body infusor for outpatient self-administration.
Quality of YouTube Medical Videos Often Poor for Patient Education
Quality of YouTube videos for patients considering an implantable cardioverter defibrillator found to be highly variable, poor overall
August 2022 Recap: Drug Pipeline Update
Stay up-to-date on the latest drugs in development.
Acetazolamide Helps Treat Volume Overload in Heart Failure
Rate of successful decongestion higher with addition of acetazolamide to loop diuretic in patients with acute decompensated heart failure
